10:56 AM EDT, 09/30/2024 (MT Newswires) -- NervGen Pharma ( NGENF ) , developing treatments for nervous system damage, on Monday said that target enrollment of the chronic cohort in its Phase 1b/2a proof-of-concept clinical trial for its lead compound, NVG-291, in individuals with spinal cord injury (SCI) is almost complete.

"We are excited to be near completion of enrollment in the chronic cohort of our Phase 1b/2a study in SCI," said Mike Kelly, NervGen's President & CEO. "Our ongoing recruitment efforts continue to attract potential study participants into the screening process, however, forecasting enrollment has been challenging given the many variables involved as well as the novel aspects of our study design and protocol."

The company is targeting 20 trial participants. The trial is designed to evaluate the efficacy of a fixed dose of NVG-29.

Price: 2.53, Change: -0.01, Percent Change: -0.39